Announcement on change of research and development officer

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase I/II Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999
August 31, 2019
Announcement of phase II clinical trial result for ovarian cancer on OBI and Mackay Memorial Hospital cooperated Adagloxad Simolenin, OBI-822
September 16, 2019
  1. Type of personnel changed (please enter: spokesperson, acting spokesperson, important operational officer, financial officer, accounting officer, company secretary, research and development officer, or internal audit officer): Research and development officer
  2. Date of occurrence of the change: Sep 06, 2019
  3. Name, title, and resume of the replaced person: Tony Yu, Chief science officer
  4. Name, title, and resume of the replacement: Ming-Tain Lai, Chief science officer; Senior chief scientist in Merk, PhD in Biochemistry in University of Minnesota/ Post doc. in Massachusetts Institute of Technology.
  5. Type of the change (please enter: “resignation”, “position adjustment”,“dismissal”, “retirement”, “death” or “new replacement” ): Position adjustment
  6. Reason for the change: Position adjustment
  7. Effective date: Sep 06, 2019
  8. Contact telephone number of the replacement: (02)2655-8799
  9. Any other matters that need to be specified: None